Clinical Trials Logo

Endothelial Dysfunction clinical trials

View clinical trials related to Endothelial Dysfunction.

Filter by:

NCT ID: NCT05388032 Recruiting - Clinical trials for Endothelial Dysfunction

Sodium Lowering Vascular Effects Trial

SOLVE
Start date: January 25, 2023
Phase: N/A
Study type: Interventional

The proposed mechanistic trial will test the effect of dietary sodium reduction on cardiac and vascular structure and function in those with elevated blood pressure or hypertension. Findings from this study will fill the knowledge gap on the underlying mechanisms of dietary sodium intake on cardiovascular disease risk in addition to blood pressure and could provide further evidence on sodium reduction for the prevention of cardiovascular disease.

NCT ID: NCT05379608 Recruiting - Hypertension Clinical Trials

Intermittent Hypoxic-hyperoxic Training in Patients With Cardiovascular Pathology After COVID-19 Infection.

Start date: December 10, 2021
Phase: N/A
Study type: Interventional

Aim of this prospective, interventional, single-center, randomized study is to evaluate the efficacy and safety of intermittent hypoxic-hyperoxic training (IHHT) as a rehabilitation method in patients with cardiovascular pathology in the early period after coronavirus infection. The study will include 60 patients with cardiovascular pathology who underwent confirmed by laboratory tests COVID-19 infection 1-3 months ago with the degree of lung lesion CT3, CT4, who were admitted to the University Clinical Hospital No. 4 of I.M. Sechenov First Moscow State Medical University. The patients will be divided into 2 groups (intervention and control groups). Intervention group will inhale hypoxic gas mixtures (10-12% O2) followed by exposure to a hyperoxic gas mixture with 30-35% O2 5 times a week for 3 weeks, while control group will undergo a simulated IHHT. All the patients will undergo identical laboratory and instrumental testing before IHHT, after the last IHHT procedure, in a month after the last IHHT procedure and in 6 months. Estimated result of the study is to confirm or refute the hypothesis of the study that a three-week course of IHHT in patients with cardiovascular pathology in the early period after coronavirus infection can improve exercise tolerance, as well as the quality of life and psychoemotional status, and affect the dynamics of laboratory and instrumental parameters.

NCT ID: NCT05371925 Recruiting - Clinical trials for Endothelial Dysfunction

Endothelial Protection in Post COVID-19 Patients With Sulodexide

Start date: July 26, 2022
Phase: Phase 3
Study type: Interventional

This is a Prospective, multicenter, randomized (1:1, placebo use) trial with a parallel-group design to assess if the use of sulodexide influences serum levels of biomarkers for endothelial dysfunction on convalescent COVID-19 patients who suffered a moderate (or more severe) clinical presentation and have chronic comorbidities of high risk for endothelial dysfunction. The recruitment period is estimated at 6 months. The follow-up period of all participants will be 8 weeks. The participant will receive according to group allocation after randomization 1. study group: sulodexide oral dose of 250LRU capsule bid for 8 weeks. 2. control group: placebo oral dose of 1 capsule bid for 8 weeks. Participants in both groups will continue the standard of care recommended by national healthcare guidelines for each Country, including any concomitant medication indicated by their primary physician.

NCT ID: NCT05366933 Recruiting - Clinical trials for Endothelial Dysfunction

B-Complex: A Nutraceutical SANS Countermeasure

Start date: August 1, 2022
Phase: Phase 1
Study type: Interventional

In this project, the investigators propose to test effectiveness of a daily nutraceutical supplement containing bioactive B vitamins to mitigate optic disc edema in astronauts. The proposed countermeasure is intended to maximize functioning of the one-carbon metabolic pathway to provide enough substrate and cofactors to overcome any genetic differences that may impact the efficiency of enzyme function. By optimizing the pathway, this will 1) optimize endothelial function by increasing eNOS coupling and nitric oxide synthesis and 2) optimize collagen firmness and elasticity in the sclera and lamina cribrosa, and 3) minimize changes in total retinal thickness during and after flight. The protocol includes assessments of ocular health and function, along with determinants of vascular endothelial function, advanced glycation end products, and nutritional status and one carbon biochemistry. These additional measures will be critical for the further definition of the causes of optic disc edema in some astronauts after long-duration space flight, and in understanding the effect of the countermeasure. Finally, the supplemented subjects in this study will be compared against total retinal thickness data from previously flown astronauts known to have not taken supplements during their missions.

NCT ID: NCT05365607 Recruiting - Clinical trials for Cardiovascular Diseases

NightWare and Cardiovascular Health in Adults With PTSD

Start date: June 24, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether NightWare therapeutic intervention improves biomarkers of vascular aging and autonomic function in adults with nightmares related to PTSD.

NCT ID: NCT05344573 Recruiting - Acute Kidney Injury Clinical Trials

Optimizing Pulsatility During Cardiopulmonary Bypass

Start date: July 5, 2022
Phase:
Study type: Observational

Cardiopulmonary bypass during cardiac surgery provides blood flow to the body during surgery but has adverse effects on different organs. Blood flow during cardiopulmonary bypass may be pulsatile or non-pulsatile, which may impact normal organ function after surgery. The study will collect data on the type of cardiopulmonary bypass used during surgery and organ function to determine if there is an association between the type of bypass and organ function.

NCT ID: NCT05331443 Enrolling by invitation - Clinical trials for Endothelial Dysfunction

Effects of Ramadan Fasting on Endothelial Function

Start date: March 15, 2022
Phase:
Study type: Observational [Patient Registry]

Include participants who intend to practice Ramadan fasting and accept to complete the three part of the study .

NCT ID: NCT05288361 Recruiting - Clinical trials for Endothelial Dysfunction

The DISCOVER INOCA Prospective Multi-center Registry

DISCOVER INOCA
Start date: September 14, 2022
Phase:
Study type: Observational [Patient Registry]

The overall objective of this multi-center registry is to identify specific phenotypes of INOCA with both an anatomic evaluation (coronary angiography and intravascular imaging) and physiologic assessment with the Abbott Coroventis Coroflow Cardiovascular System, and to determine long-term outcomes.

NCT ID: NCT05284110 Recruiting - Clinical trials for Rheumatoid Arthritis

Breaking up Sedentary Time in Rheumatoid Arthritis

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

This study will verify the effects of breaking up sitting time with short bouts of light intensity walking on vascular function in women with rheumatoid arthritis.

NCT ID: NCT05252923 Recruiting - COVID-19 Clinical Trials

Endothelial Protection in Convalescent COVID-19 Patients

Start date: April 1, 2022
Phase: Phase 4
Study type: Interventional

This pilot open-label randomized controlled trial aims to assess if treatment with sulodexide may improve the endothelial status and inflammatory response in post-COVID-19 patients. Survived inpatients with severe-to-critical COVID-19 within 14 days after discharge are randomized to receive sulodexide 250 LSU 1 oral capsule twice daily or no treatment for 8 weeks. Biomarkers of endothelial dysfunction, inflammation, and prothrombotic changes are assessed at 0, 4, and 8 weeks. The hypothesis is that affected endothelial function, pro-inflammatory, and pro-thrombotic changes could be improved with sulodexide treatment in convalescent COVID-19 patients who suffered a severe-to-critical clinical presentation and have chronic comorbidities of high risk for endothelial dysfunction.